Botched Enrollment Seen as Ruining Big Xarelto Trial

(MedPage Today) -- The failure of low-dose rivaroxaban (Xarelto) in the international COMMANDER-HF trial was traced back to aberrant patient recruiting practices and poor medication adherence in the largest enrolling region, one group found.
Study...